A Call for Nuance in Cardioprotection With Early Breast Cancer Therapy – MedPage Today

For low-risk breast cancer patients getting potentially cardiotoxic treatment, candesartan’s (Atacand) short-term protection of cardiac function faded longer term in the PRADA trial.
Left ventricular ejection fraction (LVEF) declined a similar amount from baseline to 23 months post-randomization for patients given candesartan during adjuvant breast cancer treatment versus those who were not (1.7 vs 1.8 percentage points, P=0.91), reported Siri Heck, MD, PhD, of Akershus University Hospital in Lørenskog,…

Click here to view the original article.